---
schema_version: "secwatch.filing_event.v1"
accession: "0001404644-24-000024"
form_type: "8-K"
ticker: "NGNE"
cik: "0001404644"
company_name: "Neurogene Inc."
filed_at: "2024-03-18T23:59:59+00:00"
generated_at: "2026-06-04T14:52:03.643550+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Neurogene reports FY2023 net loss $36.3M; Rett gene therapy trial expanded, cash runway to H2 2026

## Summary
- Cash and investments $197.2M at Dec 31, 2023; reverse merger and $95M private placement completed December 2023.
- FY2023 net loss $36.3M vs $55.2M prior year; Q4 net income $2.4M from $16.4M bargain purchase gain.
- R&D expenses $44.4M (down from $47.5M), G&A $11.2M (up from $9.0M) due to reverse merger costs.
- Phase 1/2 NGN-401 Rett syndrome trial expanded with high-dose Cohort 2; interim clinical data expected 4Q24.
- Appointed Dr. Julie Jordan as CMO; CLN5 Batten disease trial interim data and regulatory update expected H2 2024.

## SEC filing metadata
- accession: 0001404644-24-000024
- form_type: 8-K
- ticker: NGNE
- cik: 0001404644
- company_name: Neurogene Inc.
- filed_at: 2024-03-18T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 2.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1404644/000140464424000024/0001404644-24-000024-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1404644/000140464424000024/ngne-20240318.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001404644-24-000024
- JSON: https://secwatch.observer/filing/0001404644-24-000024.json
- Plain text: https://secwatch.observer/filing/0001404644-24-000024.txt

## Key facts
- Earnings Releases
  Neurogene Inc. reported year ended December 31, 2023 results: net income net loss was $36.3 million for the twelve months ended December 31, 2023.
  - Period: year ended December 31, 2023
  - Net income: net loss was $36.3 million for the twelve months ended December 31, 2023
  - Result: reported results
  source text: Neurogene Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Updates
  evidence_url: https://www.sec.gov/Archives/edgar/data/1404644/000140464424000024/0001404644-24-000024-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.